Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 23 tags : Cancer save search
Asher Raises $55 Million Series A for Targeted Cancer Immunotherapies
Published: 2021-03-23 (Crawled : 19:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.2%
H: 0.22%
C: -1.32%
cancer immunotherapy
GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
Published: 2021-03-23 (Crawled : 18:00) - biospace.com/
GRFS | News | $6.53 -0.76% -0.77% 760K
|
Health Technology
|
| O: 3.13%
H: 1.82%
C: 1.7%
cancer research
Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
Published: 2021-03-23 (Crawled : 13:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.89%
H: 1.96%
C: -4.53%
prostate cancer cancer granted grant
CellMax Life and Sebela Pharmaceuticals Enter Strategic Development and Commercialization Partnership for FirstSight™ Blood Test for Detection of Colorectal Cancer and Pre-Cancer
Published: 2021-03-23 (Crawled : 12:00) - biospace.com/
AFL | News | $80.98 0.9% 0.0% 2.1M
|
Finance
|
| O: -0.67%
H: 0.5%
C: -1.41%
partnership blood commercialization test cancer colorectal cancer
Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference
Published: 2021-03-23 (Crawled : 11:00) - biospace.com/
GLSI | $13.12 0.54% 0.53% 42K
|
Health Technology
|
| O: 0.29%
H: 5.25%
C: -0.29%
cancer biotech ceo iot conference leo
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
Published: 2021-03-23 (Crawled : 11:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.15%
H: 0.25%
C: -2.08%
treatment therapy cancer growth approval
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Published: 2021-03-23 (Crawled : 07:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.35%
H: 0.95%
C: 0.06%
prostate cancer positive therapy cancer
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.